AlphaCrest Capital Management’s Exact Sciences EXAS Stock Holding History

AlphaCrest Capital Management’s Portfolio EXAS Stock Details EXAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-15,647	Closed	-$508K	–	389
2022 Q3	$508K	Sell	15,647 -5,167	-25%	-$213K	0.03%	971
2022 Q2	$820K	Buy	20,814 +12,030	+137%	+$643K	0.04%	750
2022 Q1	$614K	Sell	8,784 -21,086	-71%	-$1.54M	0.03%	794
2021 Q4	$2.33M	Buy	29,870 +21,870	+273%	+$1.93M	0.09%	346
2021 Q3	$764K	Buy	8,000 +535	+7%	+$56.5K	0.04%	736
2021 Q2	$928K	Buy	7,465 +2,965	+66%	+$354K	0.04%	699
2021 Q1	$593K	Sell	4,500 -3,326	-42%	-$455K	0.03%	725
2020 Q4	$1.04M	Buy	7,826 +1,203	+18%	+$145K	0.09%	303
2020 Q3	$675K	Buy	6,623 +2,222	+50%	+$192K	0.07%	428
2020 Q2	$383K	Buy	+4,401	New	+$352K	0.06%	506
2020 Q1	–	Sell	-6,039	Closed	-$558K	–	1093
2019 Q4	$558K	Buy	6,039 +1,352	+29%	+$119K	0.05%	719
2019 Q3	$424K	Buy	+4,687	New	+$534K	0.03%	992

Other funds holding EXAS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

AlphaCrest Capital Management's EXAS Position: Q4 2022 in Review

AlphaCrest Capital Management sold out of Exact Sciences (EXAS) in Q4 2022, closing a stake of 15,647 shares — an estimated $508K sold.

AlphaCrest Capital Management first reported a position in EXAS in Q3 2019 and held it in 12 quarters. The position peaked at $2.33M in Q4 2021. 551 funds tracked by Wall St. Rank hold EXAS as of Q4 2022.

AlphaCrest Capital Management reported no remaining Exact Sciences position as of Q4 2022 after selling out during the quarter.
AlphaCrest Capital Management sold 15,647 Exact Sciences shares in Q4 2022, an estimated $508K.
AlphaCrest Capital Management first reported a position in Exact Sciences in Q3 2019 and held it in 12 quarters.
AlphaCrest Capital Management's Exact Sciences position peaked at $2.33M in Q4 2021.
551 funds tracked by Wall St. Rank held Exact Sciences as of Q4 2022.

Based on AlphaCrest Capital Management's 13F filing for Q4 2022.